6 results on '"Jöhrens, Korinna"'
Search Results
2. Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.
- Author
-
Hess, Anne-Kathrin, Jöhrens, Korinna, Zakarneh, Andre, Balermpas, Panagiotis, Von Der Grün, Jens, Rödel, Claus, Weichert, Wilko, Hummel, Michael, Keilholz, Ulrich, Budach, Volker, and Tinhofer, Ingeborg
- Subjects
- *
CHEMORADIOTHERAPY , *PHARYNGEAL cancer , *SQUAMOUS cell carcinoma , *BIOMARKERS , *TUMOR microenvironment , *TUMORS - Abstract
Background: Intra-tumoral CD8 + T-cell infiltration in squamous cell carcinoma of the head and neck (HNSCC) has previously been linked to the efficacy of cisplatin-based chemoradiation (CDDP-CRTX) and immune checkpoint inhibitor (ICI) monotherapy. Further detailed characterization of the tumor immune-micromilieu and its influence on outcome may guide the development of CRTX-ICI combinations. Methods: Comprehensive immune transcriptome analysis was applied to a training set of tumor specimens from oropharyngeal squamous cell carcinoma (OPSCC) patients treated with CDDP-CRTX in the ARO-0401 phase III study (n = 33). A composite immune signature risk score (ISRS) for survival prediction was developed, and subsequently validated in two independent OPSCC cohorts treated with either CDDP-CRTX (n = 36) or mitomycin-based CRTX (MMC-CRTX, n = 31). Further validation of the ISRS was performed in the OPSCC subset (n = 79) of the TCGA HNSCC cohort. Potential interference between immune signatures and HPV status was evaluated in multivariate Cox regression models. Results: Significant differences according to the 3-y OS status in the abundance of tumor-infiltrating T- and B-cells, and the expression levels of 51 immune-related genes were observed. A risk score based on 13 differentially expressed genes involved in cytokine signaling, T-cell effector functions and the TNFR pathway was established as robust predictive factor of OS. Its predictive power was superior to the 6-gene interferon-gamma signature of ICI efficacy and independent of the HPV status. Conclusions: This study further elucidates the complex interaction of the tumor immune microenvironment with the efficacy of CDDP-CRTX in OPSCC. The results suggest immune markers for selection of patients treated with CRTX-ICI combinations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Wideband MRE and static mechanical indentation of human liver specimen: Sensitivity of viscoelastic constants to the alteration of tissue structure in hepatic fibrosis.
- Author
-
Reiter, Rolf, Freise, Christian, Jöhrens, Korinna, Kamphues, Carsten, Seehofer, Daniel, Stockmann, Martin, Somasundaram, Rajan, Asbach, Patrick, Samani, Abbas, and Sack, Ingolf
- Subjects
- *
MAGNETIC resonance , *VISCOELASTICITY , *HEPATIC fibrosis , *BIOMARKERS , *FATTY degeneration , *YOUNG'S modulus , *HYDROXYPROLINE - Abstract
Despite the success of elastography in grading hepatic fibrosis by stiffness related noninvasive markers the relationship between viscoelastic constants in the liver and tissue structure remains unclear. We therefore studied the mechanical properties of 16 human liver specimens with different degrees of fibrosis, inflammation and steatosis by wideband magnetic resonance elastography (MRE) and static indentation experiments providing the specimens' static Young's modulus (E), dynamic storage modulus (G0) and dynamic loss modulus (G"). A frequency-independent shear modulus μ and a powerlaw exponent a were obtained by fitting G and G" using the two-parameter sprinpot model. The mechanical parameters were compared to the specimens' histology derived parameters such as degree of Fibrosis (F), inflammation score and fat score, amount of hydroxyproline (HYP) used for quantification of collagen, blood markers and presurgery in vivo function tests. The frequency averaged parameters G', G" and μ were significantly correlated with F (G': R=0.762, G": R=0.830; μ: R=0.744; all P < 0.01) and HYP (G': R=0.712; G": R=0.720; μ: R=0.731 ; all P < 0.01). The powerlaw exponent a displayed an inverse correlation with F (R = -0.590, P= 0.034) and a trend of inverse correlation with HYP (R = -0.470, P=0.089). The static Young's modulus E was less correlated with F (R=0.587, P=0.022) and not sensitive to HYP. Although inflammation was highly correlated with F (R = 0.773, P < 0.001), no interaction was discernable between inflammation and mechanical para-meters measured in this study. Other histological and blood markers as well as liver function test were correlated with neither F nor the measured mechanical parameters. In conclusion, viscoelastic constants measured by wideband MRE are highly sensitive to histologically proven fibrosis. Our results suggest that, in addition to the amount of connective tissue, subtle structural changes of the viscoelastic matrix determine the sensitivity of mechanical tissue properties to hepatic fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
- Author
-
Lamping, Mario, Benary, Manuela, Leyvraz, Serge, Messerschmidt, Clemens, Blanc, Eric, Kessler, Thomas, Schütte, Moritz, Lenze, Dido, Jöhrens, Korinna, Burock, Susen, Klinghammer, Konrad, Ochsenreither, Sebastian, Sers, Christine, Schäfer, Reinhold, Tinhofer, Ingeborg, Beule, Dieter, Klauschen, Frederick, Yaspo, Marie-Laure, Keilholz, Ulrich, and Rieke, Damian T.
- Subjects
- *
TUMOR diagnosis , *BIOMARKERS , *CANCER patients , *GENETIC counseling , *IMMUNOHISTOCHEMISTRY , *MEDICAL care , *MOLECULAR biology , *PATIENTS , *EVIDENCE-based medicine , *WORKFLOW , *TREATMENT effectiveness , *INDIVIDUALIZED medicine , *SEQUENCE analysis - Abstract
Reliable and reproducible interpretation of molecular aberrations constitutes a bottleneck of precision medicine. Evidence-based decision management systems may improve rational therapy recommendations. To cope with an increasing amount of complex molecular data in the clinical care of patients with cancer, we established a workflow for the interpretation of molecular analyses. A specialized physician screened results from molecular analyses for potential biomarkers, irrespective of the diagnostic modality. Best available evidence was retrieved and categorized through establishment of an in-house database and interrogation of publicly available databases. Annotated biomarkers were ranked using predefined evidence levels and subsequently discussed at a molecular tumour board (MTB), which generated treatment recommendations. Subsequent translation into patient treatment and clinical outcomes were followed up. One hundred patients were discussed in the MTB between January 2016 and May 2017. Molecular data were obtained for 70 of 100 patients (50 whole exome/RNA sequencing, 18 panel sequencing, 2 immunohistochemistry (IHC)/microsatellite instability analysis). The MTB generated a median of two treatment recommendations each for 63 patients. Thirty-nine patients were treated: 6 partial responses and 12 stable diseases were achieved as best responses. Genetic counselling for germline events was recommended for seven patients. The development of an evidence-based workflow allowed for the clinical interpretation of complex molecular data and facilitated the translation of personalized treatment strategies into routine clinical care. The high number of treatment recommendations in patients with comprehensive genomic data and promising responses in patients treated with combination therapy warrant larger clinical studies. • Evidence-based, flexible workflow for the clinical interpretation of molecular data. • Application to complex data including whole-exome sequencing and RNA-Sequencing in clinical routine. • Initiation of targeted treatment in 39% of patients. • Promising responses in a subset of patients. • Standardisation of precision oncology workflows could help improve prospective trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
- Author
-
Stanske, Mandy, Wienert, Stephan, Castillo-Tong, Dan Cacsire, Kreuzinger, Caroline, Vergote, Ignace, Lambrechts, Sandrijne, Gabra, Hani, Gourley, Charlie, Ganapathi, Ram N., Kolaschinski, Ivonne, Budczies, Jan, Sehouli, Jalid, Ruscito, Ilary, Denkert, Carsten, Kulbe, Hagen, Schmitt, Wolfgang, Jöhrens, Korinna, Braicu, Ioana, and Darb-Esfahani, Silvia
- Subjects
- *
IMMUNE response , *OVARIAN cancer , *CANCER invasiveness , *BIOMARKERS , *IMMUNOHISTOCHEMISTRY - Abstract
PURPOSE: Tumor-infiltrating lymphocytes (TILs) have an established impact on the prognosis of high-grade serous ovarian carcinoma (HGSOC), however, their role in recurrent ovarian cancer is largely unknown. We therefore systematically investigated TIL densities and MHC class I and II (MHC1, 2) expression in the progression of HGSOC. EXPERIMENTAL DESIGN: CD3+, CD4+, CD8+ TILs and MHC1, 2 expression were evaluated by immunohistochemistry on tissue microarrays in 113 paired primary and recurrent HGSOC. TILs were quantified by image analysis. All patients had been included to the EU-funded OCTIPS FP7 project. RESULTS: CD3+, CD4+, CD8+ TILs and MHC1 and MHC2 expression showed significant correlations between primary and recurrent tumor levels (Spearman rho 0.427, 0.533, 0.361, 0.456, 0.526 respectively; Pb.0001 each). Paired testing revealed higher CD4+ densities and MHC1 expression in recurrent tumors (Wilcoxon P=.034 and P=.018). There was also a shift towards higher CD3+ TILs levels in recurrent carcinomas when analyzing platinum-sensitive tumors only (Wilcoxon P=.026) and in pairs with recurrent tumor tissue from first relapse only (Wilcoxon P=.031). High MHC2 expression was the only parameter to be significantly linked to prolonged progression-free survival after first relapse (PFS2, log-rank P=.012). CONCLUSIONS: This is the first study that analyzed the development of TILs density and MHC expression in paired primary and recurrent HGSOC. The level of the antitumoral immune response in recurrent tumors was clearly dependent on the one in the primary tumor. Our data contribute to the understanding of temporal heterogeneity of HGSOC immune microenvironment and have implications for selection of samples for biomarker testing in the setting of immune-targeting therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®).
- Author
-
Petersen, Iver, Dietel, Manfred, Geilenkeuser, Wolf J., Mireskandari, Masoud, Weichert, Wilko, Steiger, Katja, Scheel, Andreas H., Büttner, Reinhard, Schirmacher, Peter, Warth, Arne, Lasitschka, Felix, Schildhaus, Hans-Ulrich, Kirchner, Thomas, Reu, Simone, Kreipe, Hans, Länger, Florian, Tiemann, Markus, Schulte, Christoph, and Jöhrens, Korinna
- Subjects
- *
CANCER treatment , *NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *CISPLATIN , *BIOMARKERS , *IMMUNOHISTOCHEMISTRY , *IMMUNOSTAINING - Abstract
Background EGFR and its downstream signaling pathway are important targets for cancer therapy. Recently, the monoclonal anti-EGFR antibody Necitumumab in combination with gemcitabine and cisplatin was approved (EMA/14106/2016) for first-line treatment of squamous non-small cell carcinoma (SqNSCLC). Eligibility was restricted to cases with positive EGFR expression. In this context, a ring trial of the Quality Assurance Initiative for Pathology (QuIP ® ) was launched to prepare the German pathology community for a reliable and reproducible, immunohistochemically based biomarker test. Materials and methods The trial was set up by a three-step approach. Two lead institutes were nominated to organize the trial process and to select appropriate cancer samples. These were first tested by the H-score (range 0–300) to identify positive and negative cases. Seven additional pathology institutes with experience in EGFR immunohistochemistry each tested the selected panel of identical cases (internal ring trial) to confirm the suitability of samples and scoring criteria. Then the open ring trial for all institutes of pathology in German speaking countries was announced. Results For the internal trial 8 EGFR-positive and 2 negative lung sqNSCLC samples were selected. A cut-off value of cell membranous staining in ≥ 1% of tumor cells was introduced to define a case as EGFR negative or positive. Two points were attainable per correctly assessed sample leading to a maximum of 20 points, ≥ 18 points were required for a successful participation. All 7 panel institute passed this barrier, 5 with the maximum of 20 points and two with one error (18 points) being related to one case with incorrect interpretation of cytoplasmic versus membranous staining and one case with an H-score of 2 as being considered EGFR positive. A second cut-off value (H-score ≥ 3) was therefore introduced. In the open ring trial, 34 institutions participated of which 28 were successful according to the above criteria. The trial revealed a high reproducibility despite the use of different EGFR antibodies and detection systems. There was no association between technical parameters and trial failure. Again, one participant misinterpreted the subcellular EGFR localization. Conclusions The first nationwide ring test for determination of EGFR IHC expression in sqNSCLC could be successfully performed in a very tight time frame. By this, the national pathology community was prepared to incorporate this marker in the panel of predictive cancer tests in a quality assessed manner and to initiate and accompany future studies on EGFR pathway pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.